Gilead's Epclusa for HCV could impact Daklinza market, PPI concerns unlikely reimbursement issue – experts

09 Aug 2016

Gilead Sciences’ (NASDAQ:GILD) hepatitis C (HCV) drug Epclusa’s (sofosbuvir/velpatasvir) appealing pricing to US payers could affect Bristol-Myers Squibb (NYSE:BMY) Daklinza’s (daclatasvir) market share, experts said. They noted Epclusa will unlikely face pricing and reimbursement barriers over potential diminished efficacy concerns for patients taking proton pump inhibitors (PPI).

Access barriers to Epclusa are still inevitable as its USD 75k price tag is still expensive even if it is relatively cheaper than current HCV treatments, experts added. Meanwhile BMS could put a spotlight on Epclusa’s PPI coadministration issues to protect its sales but solid data is needed for this to gain payer confidence, they said.

Epclusa features sofosbuvir (nucleotide polymerase inhibitor) and velpatasvir (pan-genotypic NS5A inhibitor), the company website shows. Daklinza features daclatasvir and is also an NS5A inhibitor, BMS’ website shows.

The FDA approved Epclusa on 28 June for all HCV genotypes. This news service reported 28 July Epclusa upholds its positive market potential even if coadministration of generic omeprazole or other PPIs is not recommended as it could pose potentially significant drug interaction.

Already a subscriber? Login to read the full article.